Experimental Alzheimer's drug ALZ-801 slows cognitive decline in high-risk patients

An experimental pill, ALZ-801, showed promise in a trial, potentially slowing memory decline by 50% in early Alzheimer's patients with a specific gene. The trial involved individuals with mild cognitive impairment and two copies of the APOE4 gene, also reducing brain shrinkage by 18% in this subgroup. ALZ-801 works by preventing amyloid plaque formation, offering a potential alternative to IV infusion treatments and avoiding side effects like brain swelling seen with other drugs.